Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 11, 2023 (filed on Apr 12, 2023)Insider Name:Adams R MarkOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,308Price:$8.63
-
Apr 10, 2023 (filed on Apr 12, 2023)Insider Name:Adams R MarkOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-817Price:$8.50
-
Mar 27, 2023 (filed on Mar 29, 2023)Insider Name:Griffin Michelle ReneeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,341Price:$8.49
-
Mar 07, 2023 (filed on Mar 08, 2023)Insider Name:Taylor Stacy LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13,387Price:$8.60
-
Mar 07, 2023 (filed on Mar 08, 2023)Insider Name:Adams R MarkOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17,155Price:$8.60
-
Mar 07, 2023 (filed on Mar 08, 2023)Insider Name:Sood NitinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,813Price:$8.60
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Pellini Michael JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,329Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Pellini Michael JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,775Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Owen Katey EinterzOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,329Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Owen Katey EinterzOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,775Price:--
Filings by filing date
-
Apr 11, 2023 (filed on Apr 12, 2023)Insider Name:Adams R MarkOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,308Price:$8.63
-
Apr 10, 2023 (filed on Apr 12, 2023)Insider Name:Adams R MarkOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-817Price:$8.50
-
Mar 27, 2023 (filed on Mar 29, 2023)Insider Name:Griffin Michelle ReneeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,341Price:$8.49
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Pellini Michael JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,329Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Pellini Michael JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,775Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Owen Katey EinterzOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,329Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Owen Katey EinterzOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,775Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,329Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Neupert Peter MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,775Price:--
-
Mar 06, 2023 (filed on Mar 08, 2023)Insider Name:Hershberg RobertOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,329Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1165 Eastlake Ave E SEATTLE WA 98109 |
Tel: | 1-650-8251656 |
Website: | https://www.adaptivebiotech.com |
IR: | See website |
Key People | ||
Chad M. Robins Chairman of the Board, Chief Executive Officer, Co-Founder | Julie Rubinstein President | Harlan S. Robins Co-Founder, Chief Scientific Officer |
Tycho Peterson Chief Financial Officer | Francis Lo Chief People Officer | Stacy Taylor Senior Vice President, General Counsel |
Sharon Benzeno Chief Commercial Office - Immune Medicine | Nitin Sood Chief Commercial Officer - MRD |
Business Overview |
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). |
Financial Overview |
For the three months ended 31 March 2023, Adaptive Biotechnologies Corp revenues decreased 3% to $37.6M. Net loss decreased 8% to $57.7M. Revenues reflect Immune meidicine revenue segment decrease of 22% to $16.2M. Lower net loss reflects General and administrative - Balancing decrease of 21% to $15.4M (expense), Personnel expenses decrease of 22% to $14.5M (expense). |
Employees: | 790 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $762.87M as of Mar 31, 2023 |
Annual revenue (TTM): | $184.34M as of Mar 31, 2023 |
EBITDA (TTM): | -$172.34M as of Mar 31, 2023 |
Net annual income (TTM): | -$195.15M as of Mar 31, 2023 |
Free cash flow (TTM): | -$194.84M as of Mar 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 144,311,000 as of Apr 28, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |